

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

EQA round: AP1/18 - Antithrombotic Agents

Dead line: 16.03.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set of samples 1														
(108) Apixaban	[µg/L]				20							20	19	95%
Samples and groups														
Sample A1		200	17	8,5	20	CVP	200	9,3	25%	150	250	20	19	95%
(2) Chromogenous substrat		200	17	8,5	20	0						20		
Sample B1		416	27	6,5	20	CVP	416	15	25%	312	520	20	20	100%
(2) Chromogenous substrat		416	27	6,5	20	0						20		
Set of samples 2														
(109) Dabigatran	[µg/L]				26							26	26	100%
Samples and groups														
Sample A2		101	12	11	26	CVP	101	5,5	25%	75,7	127	26	26	100%
(1) Coagulometer		105	8,1	7,8	20	0						20		
(2) Chromogenous substrat		89,0	4,5	5,1	6	0						6		
Sample B2		303	35	11	26	CVP	303	17	25%	227	379	26	26	100%
(1) Coagulometer		314	25	8,1	20	0						20		
(2) Chromogenous substrat		264	8,2	3,1	6	0						6		
Set of samples 3														
(110) Rivaroxaban	[µg/L]				30							30	28	93%
Samples and groups														
Sample A3		94,9	11	12	30	CVP	94,9	5,0	25%	71,1	119	30	28	93%
(2) Chromogenous substrat		94,9	11	12	30	0						30		
Sample B3		299	25	8,3	30	CVP	299	11	25%	224	374	30	30	100%
(2) Chromogenous substrat		299	25	8,3	30	0						30		

st_kn_p

End of report

Printed: 22.03.2018